Ligandscout 4.3 _best_

One of the most celebrated hidden features of is its new PDB (Protein Data Bank) preprocessing engine.

, virtual screening, and molecular docking. It is developed by Inte:Ligand ligandscout 4.3

| Feature | LigandScout 4.3 | MOE 2024 | Phase (Schrödinger) | | :--- | :--- | :--- | :--- | | | Fully automated | Semi-automated | Manual heavy | | GNN-based Scoring | Yes (DeepScoring 2.0) | No | No (uses docking) | | Cryo-EM Density Support | Native | Via plugin only | Yes | | CLI for HPC | Yes (Full suite) | Limited | Yes | | Cost (Academic) | Mid-range (~$5k) | High (~$15k) | High (~$25k) | One of the most celebrated hidden features of

When a target structure is unknown, the platform builds models based entirely on known active chemical entities. In Silico Approaches to Identify Agonist Compounds - HAL In Silico Approaches to Identify Agonist Compounds -

A 2024 pre-print from the University of Barcelona utilized to identify novel ROCK1 inhibitors. Using a structure-based pharmacophore derived from PDB: 2ETR, the team screened a library of 2.5 million compounds in 14 hours on a single workstation (Intel i9, 128GB RAM, RTX 4080). The top 10 scoring compounds (by DeepScoring 2.0) were tested in vitro . Three had IC50 values below 500 nM, and one provided a novel scaffold (patent pending). The researchers explicitly noted that version 4.2 had previously failed to map the solvent-excluded volume correctly for this target, leading to false negatives.

Note: LigandScout has since evolved beyond version 4.3 (current releases include 4.4 and 5.x), but 4.3 remains widely cited in academic literature for its robust pharmacophore performance.

[3D Crystal Complex] ──> [Pocket & Interaction Analysis] ──> [Structure-Based Pharmacophore] Ligand-Based Pharmacophore Modeling